Tag: oncolytic virus therapy market

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Oncolytic Virus Therapy Market Size Likely To Evolve From 2025 Through 2034?

The oncolytic virus therapy market size has experienced significant expansion in recent years. This market is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, showing a compound annual growth rate (CAGR) of 25.0%. The growth observed historically can be attributed to several factors including improved genetic engineering techniques, a heightened understanding of the tumor microenvironment, successful clinical outcomes and regulatory greenlights, the increasing prominence of immunotherapy in cancer treatment, and innovations in gene delivery systems.

The oncolytic virus therapy market size is anticipated to undergo significant expansion in the next few years. It is projected to reach $0.55 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 23.7%. The expected rise during this forecast period can be attributed to several factors, including the proliferation of oncolytic virus platforms, the use of combination therapies with immune checkpoint inhibitors, personalized medicine approaches, the broadening of the clinical trial landscape, and supportive regulatory guidelines. Key trends anticipated in the forecast period encompass technological advances in delivery systems, advancements in synthetic biology, collaborations and partnerships within the biopharmaceutical industry, progress in virology and immunology, and an increased focus on pediatric oncology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Industry Drivers Are Expected To Accelerate The Oncolytic Virus Therapy Market From 2025 To 2029?

The escalating incidence of cancer cases is anticipated to drive the expansion of the oncolytic virus therapy market moving forward. Cancer denotes a spectrum of diseases identified by the uncontrolled multiplication and spread of abnormal cells within the body. Oncolytic virus therapy provides the ability to selectively target and eradicate cancer cells while simultaneously stimulating an immune response against the tumor, thereby offering a dual mechanism for effective cancer treatment. For instance, in January 2023, the American Cancer Society Inc., a US-based non-profit organization, projected 609,820 cancer deaths and 1,958,310 new cancer cases in the US during 2022. Therefore, the increasing prevalence of cancer cases is fueling the growth of the oncolytic virus therapy market.

What Are The Leading Segments Analyzed In The Oncolytic Virus Therapy Market?

The oncolytic virus therapymarket covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy; Adenovirus-Based Oncolytic Virus Therapy; Reovirus; Poxviruses; NDV (Newcastle Disease Virus); Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses; Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer; Lung Cancer; Prostate Cancer; Melanoma; Brain Tumor; Blood Cancer

4) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC); Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015; AdV-5/3-D24; Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin; Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac); Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies; Other NDV Applications

6) By Other Therapy Types: Combination Therapies; Other Emerging Oncolytic Virus Therapies

What Long-Term Trends Will Shape The Future Growth Of The Oncolytic Virus Therapy Industry?

Leading companies operating in the oncolytic virus therapy market are focusing on obtaining regulatory clearances to expedite the introduction of innovative cancer treatments. Regulatory approvals refer to the process by which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, secured Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients whose disease has progressed after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation aims to accelerate the development and review process for therapies addressing serious conditions with unmet medical needs.

Which Global Market Leaders Are Shaping The Future Of The Oncolytic Virus Therapy Sector?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Oncolytic Virus Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Anti Cancer Mabs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Solid Tumor Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Oncolytic Virus Therapy Market?

The market size for oncolytic virus therapy has seen a significant increase in recent years. The market is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, with a compound annual growth rate (CAGR) of 25.4%. The growth observed in the past is due to advancements in genetic engineering methods, enhanced knowledge of the tumor microenvironment, clinical victories and regulatory sanctions, the increasing prominence of immunotherapy in treating cancer, and progress in gene delivery systems.

What Growth Rate Is Forecasted for the Oncolytic Virus Therapy Market by 2029?

Expectations are high for a sharp rise in the size of the oncolytic virus therapy market in the next few years. With a compound annual growth rate (CAGR) of 23.7%, it is projected to reach $0.55 billion by 2029. This projected growth during the forecast period can be linked to the development of oncolytic virus platforms, the use of immune checkpoint inhibitors in combination therapies, approaches focused on personalized medicine, an increased scale of clinical trials, and regulatory support and guidelines. The forecast period also anticipates several major trends, including technological developments in delivery systems, progress in synthetic biology, collaborations, and partnerships in the biopharmaceutical industry, improvements in virology and immunology, and a greater focus on pediatric oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Key Companies Are Shaping the Future of the Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

Which Factors Are Driving Demand in the Oncolytic Virus Therapy Industry?

The rise in cancer cases is expected to drive the expansion of the oncolytic virus therapy market. Cancer refers to a collection of diseases marked by the unregulated proliferation and dispersion of abnormal cells within the body. Oncolytic virus therapy has the potential to selectively attack and eliminate cancer cells, while also triggering an immunological response against the tumor, making it a potent mechanism for cancer treatment. For example, the American Cancer Society Inc., a non-profit organization based in the US, predicts that there will be 609,820 cancer deaths and 1,958,310 fresh cancer incidents in the US throughout 2022, as of January 2023. Hence, the escalating prevalence of cancer cases is a key factor fueling the growth of the oncolytic virus therapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

How Is the Oncolytic Virus Therapy Market Segmented by Several Divisions?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

What are the Emerging Market Trends Driving the Growth of the Oncolytic Virus Therapy Industry?

Leading firms within the oncolytic virus therapy market are focusing on achieving regulatory authorizations to hasten the incorporation of pioneering cancer therapies. This essentially refers to the health authority assessment and endorsement of medical commodities such as drugs, biotech solutions, and medical devices in order to bring them to market. For example, in March 2024, Fast Track certification was granted by the FDA to ImmVira, a biotechnology firm based in China, for MVR-T3011 IT, their oncolytic virus therapy. The therapy is designed for patients suffering from recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who have experienced disease progression post-platinum-based chemotherapy and at least one preceding line of anti-PD-1/PD-L1 treatment. The goal of this certification is to speed up both the development and scrutiny process for treatments tackling serious conditions with unmet medical needs.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Regions Are Driving Growth in the Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

This Report Delivers Insight On:

1. How big is the oncolytic virus therapy market, and how is it changing globally?

2. Who are the major companies in the oncolytic virus therapy market, and how are they performing?

3. What are the key opportunities and risks in the oncolytic virus therapy market right now?

4. Which products or customer segments are growing the most in the oncolytic virus therapy market?

5. What factors are helping or slowing down the growth of the oncolytic virus therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the oncolytic virus therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Oncolytic Virus Therapy Market From 2025 To 2029?

The market size for oncolytic virus therapy has seen a significant increase in recent years. The market is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, with a compound annual growth rate (CAGR) of 25.4%. The growth observed in the past is due to advancements in genetic engineering methods, enhanced knowledge of the tumor microenvironment, clinical victories and regulatory sanctions, the increasing prominence of immunotherapy in treating cancer, and progress in gene delivery systems.

Expectations are high for a sharp rise in the size of the oncolytic virus therapy market in the next few years. With a compound annual growth rate (CAGR) of 23.7%, it is projected to reach $0.55 billion by 2029. This projected growth during the forecast period can be linked to the development of oncolytic virus platforms, the use of immune checkpoint inhibitors in combination therapies, approaches focused on personalized medicine, an increased scale of clinical trials, and regulatory support and guidelines. The forecast period also anticipates several major trends, including technological developments in delivery systems, progress in synthetic biology, collaborations, and partnerships in the biopharmaceutical industry, improvements in virology and immunology, and a greater focus on pediatric oncology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

What Are the Core Growth Drivers Propelling the Oncolytic Virus Therapy Market Forward?

The rise in cancer cases is expected to drive the expansion of the oncolytic virus therapy market. Cancer refers to a collection of diseases marked by the unregulated proliferation and dispersion of abnormal cells within the body. Oncolytic virus therapy has the potential to selectively attack and eliminate cancer cells, while also triggering an immunological response against the tumor, making it a potent mechanism for cancer treatment. For example, the American Cancer Society Inc., a non-profit organization based in the US, predicts that there will be 609,820 cancer deaths and 1,958,310 fresh cancer incidents in the US throughout 2022, as of January 2023. Hence, the escalating prevalence of cancer cases is a key factor fueling the growth of the oncolytic virus therapy market.

What Segment Types Define the Oncolytic Virus Therapy Market Structure?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theOncolytic Virus Therapy Industry Evolution?

Leading firms within the oncolytic virus therapy market are focusing on achieving regulatory authorizations to hasten the incorporation of pioneering cancer therapies. This essentially refers to the health authority assessment and endorsement of medical commodities such as drugs, biotech solutions, and medical devices in order to bring them to market. For example, in March 2024, Fast Track certification was granted by the FDA to ImmVira, a biotechnology firm based in China, for MVR-T3011 IT, their oncolytic virus therapy. The therapy is designed for patients suffering from recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who have experienced disease progression post-platinum-based chemotherapy and at least one preceding line of anti-PD-1/PD-L1 treatment. The goal of this certification is to speed up both the development and scrutiny process for treatments tackling serious conditions with unmet medical needs.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Is the Definition of the Oncolytic Virus Therapy Market?

Oncolytic virus therapy, also known as virotherapy, is a type of cancer treatment that utilizes viruses to target and destroy cancer cells in the body. The main objective of oncolytic virus therapy is to use viruses that have been genetically modified or naturally occur in a way that allows them to selectively infect and replicate within cancer cells while sparing healthy cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of the Oncolytic Virus Therapy Market from 2025 to 2034?

The upswing in the occurrences of cancer is anticipated to fuel the expansion of the oncolytic virus therapy market in the future. The term ‘cancer’ signifies a collection of diseases marked by the unchecked multiplication and dissemination of abnormal cells within the body. Oncolytic virus therapy carries the promising capacity to specifically target and eradicate cancer cells, simultaneously inducing an immune response against the tumor, thus providing an effective two-pronged approach for treating cancer. For example, the American Cancer Society Inc., a non-profit entity based in the US, predicts that in January 2023, there will be roughly 609,820 mortalities and 1,958,310 new diagnoses of cancer within the US during 2022. Consequently, the escalating instances of cancer are augmenting the growth of the oncolytic virus therapy market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

What is the Predicted Annual Growth Rate of the Oncolytic Virus Therapy Market Impact Industry Trends by 2034?

The market size of oncolytic virus therapy has seen a sharp increase in the last few years. It is projected to escalate from $0.19 billion in 2024 to $0.23 billion in 2025, marking a compound annual growth rate (CAGR) of 25.4%. The expansion during the historic period is linked to the advancement in genetic engineering methods, a deeper insight into the tumor microenvironment, successes in the clinical field and approval from regulatory bodies, the growing prominence of immunotherapy in treating cancer, and the progress in gene delivery systems.

The market for oncolytic virus therapy is predicted to witness robust growth over the next years, expanding to $0.55 billion by 2029 with a 23.7% CAGR. The forecasted growth can be linked to the broadening of oncolytic virus platforms, the pairing of therapies with immune checkpoint inhibitors, the adoption of personalized medicine strategies, expanded clinical trial fields, and support from regulations and guidelines. Noteworthy trends during this forecast period include the progression of delivery system technology, advancements in synthetic biology, increased collaboration and partnerships in the biopharmaceutical sector, virology and immunology breakthroughs, and an emphasis on pediatric oncology.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

How Are Market Trends and Innovations Revolutionizing the Oncolytic Virus Therapy Industry in Recent Times?

Leading organizations in the oncolytic virus therapy market are focusing on acquiring regulatory authorizations in order to speed up the launch of innovative cancer treatments. These regulatory permissions are the evaluation and approval processes carried out by health regulators for the commercial use of medical products, such as drugs, biologics, and healthcare devices. For instance, ImmVira, a biotech firm based in China, was granted a Fast Track status by the FDA for its MVR-T3011 IT, an oncolytic virus therapy in March 2024. This treatment is aimed at addressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who’ve seen disease progression after platinum-based chemotherapy and at least one previous anti-PD-1/PD-L1 therapy. Such Fast Track designation is aimed at accelerating the development and review of treatments for serious diseases having unfulfilled medical requirements.

Which Key Market Players Are Shaping the Future and Growth of theOncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

#thebusinessresearchcompany #marketresearch #marketintelligence

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

What Regions Are Dominating the Oncolytic Virus Therapy Market Growth?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Oncolytic Virus Therapy Market 2025, By The Business Research Company:

Cervical Cancer Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Endometrial Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the oncolytic virus therapy market grown over the years?

The market scale of oncolytic virus therapy has seen exponential growth in the past few years. The market is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, with a compound annual growth rate (CAGR) of 25.4%. Factors contributing to the historical market growth include advancements in genetic engineering methods, a heightened comprehension of the tumor microenvironment, successful clinical trials and regulatory authorization, the prominence of immunotherapy in cancer management, and progress in gene delivery technologies.

What Is the forecasted market size and growth rate for the oncolytic virus therapy market?

It is projected that the oncolytic virus therapy market will experience rapid expansion in the coming years, eventually reaching a market worth of $0.55 billion in 2029, with a compound annual growth rate of 23.7%. Various factors, such as the growth of oncolytic virus platforms, the combined treatments with immune checkpoint inhibitors, the development of personalized medicine approaches, an increase in clinical trials, and regulatory backing and guidelines contribute to this foreseen growth. Trends likely to stimulate the growth of the market during this forecast period consist of innovation in delivery systems, strides in synthetic biology, partnerships and collaborations within the biopharmacological industry, advances in virology and immunology, and a focus on pediatric oncology.

Get your oncolytic virus therapy market report here!

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What are the major factors driving growth in the oncolytic virus therapy market?

The rising number of cancer diagnoses is projected to fuel the expansion of the oncolytic virus therapy market. Cancer denotes a set of illnesses marked by the uncontrolled proliferation and diffusion of abnormal cells within the body. Oncolytic virus therapy has the capacity to selectively aim at and eliminate cancer cells, while also eliciting an immune response against the tumor. This dual-action methodology is promising for effective cancer treatment. For example, in January 2023, data from the American Cancer Society Inc., a nonprofit organization based in the US, predicts that there will be 609,820 cancer-related fatalities and 1,958,310 new cancer diagnoses in the US during 2022. Thus, the escalating prevalence of cancer diagnoses continues to spur the growth of the oncolytic virus therapy market.

What key areas define the segmentation of the global oncolytic virus therapy Market?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

What are the top market players propelling the growth of the oncolytic virus therapy industry?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

What are the key trends shaping the future of the oncolytic virus therapy market?

Key players in the oncolytic virus therapy market are focusing on obtaining necessary regulations to speed up the launch of novel cancer therapies. These regulatory approvals are part of a process in which health agencies assess and sanction medical products, including drugs, biologics, and medical equipment, for use on the market. For instance, ImmVira, a biotechnology firm based in China, was granted Fast Track approval by the FDA in March 2024 for its MVR-T3011 IT oncology virus therapy. This treatment targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have undergone disease progression following platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. The Fast Track designation aims to accelerate the development and review process for therapies that address severe conditions lacking adequate medical solutions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

What regions are dominating the oncolytic virus therapy market growth?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cervical Cancer Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Endometrial Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Oncolytic Virus Therapy Market From 2025 to 2034?

The oncolytic virus therapy market has witnessed exponential growth in recent years. It is projected to increase from $0.19 billion in 2024 to $0.23 billion in 2025, at a CAGR of 25.4%. This expansion has been driven by advancements in genetic engineering techniques, a deeper understanding of tumor microenvironments, clinical successes and regulatory approvals, the rise of immunotherapy in cancer treatment, and progress in gene delivery systems.

The oncolytic virus therapy market is forecasted to grow exponentially, reaching $0.55 billion by 2029 with a CAGR of 23.7%. Growth will be driven by the expansion of oncolytic virus platforms, the emergence of combination therapies with immune checkpoint inhibitors, advancements in personalized medicine, an increasing number of clinical trials, and favorable regulatory guidelines. Major trends will include innovations in delivery systems, progress in synthetic biology, collaborations within the biopharmaceutical sector, breakthroughs in virology and immunology, and a heightened focus on pediatric oncology.

What External and Internal Drivers Are Contributing to the Growth of the oncolytic virus therapy Market’s Growth?

The growing prevalence of cancer is also expected to boost the oncolytic virus therapy market. Oncolytic virus therapy aims to selectively target and destroy cancer cells while stimulating an immune response. According to the American Cancer Society, there will be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the U.S. in 2023. The increasing cancer prevalence is fostering the growth of the oncolytic virus therapy market.

Get Your Free Sample of the Global Oncolytic Virus Therapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

What Are the Key Industry Players Leading the Charge in the Oncolytic Virus Therapy Market’s Growth?

Major companies operating in the oncolytic virus therapy market include:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Sorrento Therapeutics Inc._x000D_

• AbbVie Inc._x000D_

• AstraZeneca plc_x000D_

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Oncolytic Virus Therapy Market?

In the oncolytic virus therapy market, major companies are focusing on obtaining regulatory approvals to accelerate the introduction of innovative cancer treatments. For example, in March 2024, ImmVira, a China-based biotechnology company, received Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have not responded to previous treatments, expediting the development and review process for therapies addressing unmet medical needs.

Get Instant Access to the Global Oncolytic Virus Therapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Are the Key Components of the Oncolytic Virus Therapy Market, and How Do Its Segments Perform?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

What Regions Are Influencing the Dynamics of the Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Elements Shape the Definition of the Oncolytic Virus Therapy Market?

Oncolytic virus therapy, also known as virotherapy, is a type of cancer treatment that utilizes viruses to target and destroy cancer cells in the body. The main objective of oncolytic virus therapy is to use viruses that have been genetically modified or naturally occur in a way that allows them to selectively infect and replicate within cancer cells while sparing healthy cells.

Browse Through More Similar Reports By The Business Research Company:

Cervical Cancer Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Endometrial Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: